Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Recruiting

Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Sponsor:

Children's Oncology Group

Code:

NCT05602194

Conditions

B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

Lymphoblastic Lymphoma

Mixed Phenotype Acute Leukemia

Eligibility Criteria

Sex: All

Age: 15 - 40

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Calaspargase Pegol

Levocarnitine

Pegaspargase

Quality-of-Life Assessment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Children's Oncology Group on 2025-03-25.